Guangzhou Fermion Technology Co., Ltd and Simcere Pharmaceutical Group Limited Enters into an Exclusive License and Collaboration Agreement for China's First Sstr4 Agonist Targeting Pain

Published: 2025-01-17 23:47:00 ET 2096.HK

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4. FZ002-037 is a highly selective oral small-molecule SSTR4 agonist developed by Fermion. Preclinical studies indicate that the drug primarily provides peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management.

It is the first domestically developed SSTR4 agonist in China and the second globally to reach the clinical stage. The drug has completed Phase I clinical trials in China, with Phase II studies for diabetic peripheral neuropathy set to begin soon. Potential applications extend to various chronic and acute pain conditions.

Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in Greater China (MainlandChina, Hong Kong, Macau, and Taiwan). Fermion will receive an upfront payment, milestone payments, and tiered royalties based on future sales.